-
This paper reports the early results from a proof-of-concept study looking at combined renal artery denervation and pulmonary vein isolation in hypertensive patients with atrial fibrillation. The authors randomized patients with drug refractory atrial fibrillation and drug-resistant hypertension to either standard pulmonary vein isolation or pulmonary vein isolation with renal artery denervation in a single procedure.
-
Drug-eluting stents (DES) reduce the rate of in-stent restenosis (ISR) compared to bare-metal stents (BMS). However, the first-generation DES had higher rates of late stent thrombosis than BMS, and this was more evident after primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI).
-
The use of non-steroidal anti-inflammatory drugs (NSAIDs) early after myocardial infarction (MI) has been shown to increase the risk of death or recurrent MI, but little is known about the long-term risks.
-
The left atrial appendage is thought to be the source of a large proportion of emboli in patients with nonvalvular atrial fibrillation. In this paper, Bartus and his colleagues describe an innovative new device that uses a combined transseptal-epicardial approach to ligate the left atrial appendage.
-
Menopausal hormone therapy and risk of VTE and AD; patients' understanding of chemotherapy benefits; and FDA actions.
-
-
-
This paper reviews the recent data on the effectiveness of cardiac resynchronization therapy (CRT) in patients with milder forms of heart failure (NYHA classes 1 and 2) and revises the Heart Failure Society of America's (HFSA) 2010 Guidelines.
-
This report from a consortium of Canadian implantable cardioverter-defibrillator (ICD) implantation centers analyzed predictors of failure of the Medtronic Sprint Fidelis lead.
-
For those who perform percutaneous coronary intervention (PCI), the newer generation stents have obvious benefits during the procedure.
